Biofrontera Inc. - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
BFRI Nasdaq 3840 www.biofrontera-us.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Biofrontera Inc.

Biofrontera (BFRI) Q1 2026 Earnings Transcript - Jun 2nd, 2026 11:16 am
Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 - May 21st, 2026 7:15 am
StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls - May 19th, 2026 7:34 am
Biofrontera Inc (BFRI) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ... - May 14th, 2026 5:04 pm
Biofrontera Inc. (BFRI) Reports Q1 Loss, Beats Revenue Estimates - May 14th, 2026 7:25 am
Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update - May 14th, 2026 5:30 am
Biofrontera Launches Second Annual “Hats On” Campaign to Raise Awareness of Actinic Keratosis - May 13th, 2026 7:00 am
Humacyte, Inc. (HUMA) Reports Q1 Loss, Misses Revenue Estimates - May 13th, 2026 6:35 am
Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026 - May 8th, 2026 2:00 pm
Rapport Therapeutics, Inc. (RAPP) Reports Q1 Loss - May 7th, 2026 6:50 am
Biofrontera Inc (BFRI) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Mar 20th, 2026 7:01 pm
Biofrontera Inc. Q4 2025 Earnings Call Summary - Mar 19th, 2026 10:44 am
Biofrontera (BFRI) Q4 2025 Earnings Transcript - Mar 19th, 2026 9:17 am
Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update - Mar 19th, 2026 7:25 am
Are Medical Stocks Lagging Align Technology (ALGN) This Year? - Mar 11th, 2026 7:40 am
Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026 - Mar 9th, 2026 3:25 pm
Biofrontera Inc. (BFRI) Upgraded to Buy: Here's Why - Mar 9th, 2026 10:00 am
Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris - Mar 9th, 2026 7:15 am
U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable - Feb 26th, 2026 7:15 am
Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities - Feb 17th, 2026 7:15 am